Color blindness is not caused by a single type of mutation. The most common form, red-green color blindness, results primarily from unequal recombination between genes on the X chromosome, which creates hybrid genes, deletes genes entirely, or swaps critical DNA segments between them. Less common types involve point mutations on other chromosomes. The specific mutation type depends on which form of color blindness you’re looking at.
The Genes Involved
Your ability to see color depends on cone cells in your retina, each tuned to a different wavelength of light: red, green, or blue. Each cone type is built using instructions from a specific gene. The red-sensing and green-sensing cone genes sit right next to each other on the X chromosome, while the blue-sensing cone gene is on chromosome 7. This arrangement matters because it determines both the types of mutations that occur and who is most likely to be affected.
Unequal Recombination: The Main Culprit
The red and green cone genes evolved from a single ancestor gene and still share an extremely high degree of similarity in their DNA sequences. They’re also arranged head-to-tail on the X chromosome. This combination of near-identical sequences sitting side by side creates a problem during cell division: the DNA strands can misalign and swap segments with the wrong partner.
This process, called unequal homologous recombination, is the primary mutation mechanism behind red-green color blindness. When DNA strands misalign and cross over, several things can happen. Whole genes can be deleted, so a person ends up with no red-sensing or no green-sensing cones at all. Hybrid genes can form, fusing parts of the red gene with parts of the green gene, producing a cone pigment that responds to the wrong wavelengths. Or critical DNA segments called exons can get swapped between the two genes, creating unusual combinations of building blocks that shift how the resulting pigment absorbs light.
These recombination events are surprisingly common across generations. They’re responsible for the full spectrum of red-green color vision deficiency, from mild shifts in color perception (anomalous trichromacy, where you have all three cone types but one doesn’t work quite right) to complete loss of one cone type (dichromacy, where red or green is simply absent).
Other Mutation Types in Red-Green Deficiency
While recombination drives most cases, other mutation types also play a role. Missense mutations, where a single DNA letter change swaps one amino acid for another in the cone protein, can inactivate a gene that would otherwise be functional. One well-documented example is a cysteine-to-arginine substitution that disables a hybrid cone gene entirely. Nonsense mutations, which introduce a premature stop signal in the gene, and partial deletions of the coding sequence have also been identified in affected families.
A particularly interesting mechanism involves gene conversion, where a segment of one gene is copied over the corresponding segment of its neighbor without the reciprocal exchange you’d see in crossover. This can transfer an inactivating mutation from one cone gene to another, knocking out both. In some families, deletions of a regulatory region called the locus control region prevent any of the downstream cone genes from being turned on at all, even though the genes themselves are intact.
Research published in Human Mutation grouped affected families into three distinct categories: locus control region deletions, inactivating missense mutations in hybrid genes, and problematic DNA-letter interchange patterns in a critical gene segment called exon 3. That last category is notable because certain combinations of common gene variants in exon 3 cause the cell’s machinery to skip that segment entirely when reading the gene, producing a nonfunctional protein.
Why Men Are Affected Far More Often
Red-green color blindness follows an X-linked recessive inheritance pattern. Since the red and green cone genes are on the X chromosome, men (who have one X and one Y) only need one defective copy to be affected. Women (with two X chromosomes) would need defective copies on both to show the same level of color vision loss. A woman with one affected X chromosome is typically a carrier with normal or near-normal color vision.
This explains the stark gender gap in prevalence. Among people of Northern European descent, roughly 8% of men have some form of red-green color vision deficiency compared to about 0.5% of women. The rates are lower in other populations: around 4.7% of boys in one Irish study, and 2.2% in a South African study. Deutan defects (involving the green-sensing pigment) are the most common subtype, affecting up to 6% of males in some populations. Protan defects (involving the red-sensing pigment) account for about 1% of males of European descent.
Blue-Yellow Color Blindness: A Different Mutation
Tritanopia, or blue-yellow color blindness, works differently. The blue cone gene sits alone on chromosome 7, so it isn’t subject to the same recombination problems as the red and green genes. Instead, tritanopia is caused by point mutations in that gene, such as a proline-to-leucine amino acid substitution that disrupts the blue cone pigment. Because it’s on a non-sex chromosome, tritanopia is inherited in an autosomal dominant pattern, meaning a single defective copy from either parent can cause it. It’s also far rarer, affecting fewer than 0.01% of people.
Achromatopsia: Complete Color Blindness
The rarest and most severe form, achromatopsia, leaves a person with no functioning cone cells at all. Everything appears in shades of gray, and the condition comes with reduced visual acuity, involuntary eye movements, and extreme light sensitivity. It affects roughly 1 in 30,000 people.
Achromatopsia is autosomal recessive, meaning you need two defective copies of the same gene (one from each parent) to be affected. Two genes account for most cases. Mutations in one tend to be missense changes that alter a single amino acid in a protein critical to how cones convert light into electrical signals. Mutations in the other are more commonly nonsense, frameshift, or splicing errors that produce truncated, nonfunctional proteins. In either case, the cone signaling pathway is broken at a fundamental level.
How Color Blindness Is Diagnosed
Most people learn they have a color vision deficiency through screening tests like pseudoisochromatic plates (those dotted-circle images with hidden numbers). These tests are good at detecting that a deficiency exists but notoriously poor at distinguishing between subtypes or severity levels. Separating someone who is completely missing green cones from someone whose green cones are just slightly off-peak has historically been one of the biggest weaknesses of standard clinical testing.
Genetic testing can now identify the exact mutation responsible. A DNA-based assay can perfectly separate red-type defects from green-type defects and reliably identify people who are completely missing a cone type versus those with a milder anomaly. The most practical approach combines a basic screening test with genetic analysis, giving both a functional picture of how someone sees and a precise molecular diagnosis of why.
Treatment Options
There is currently no approved treatment for any form of color blindness. Tinted lenses and filter glasses can enhance contrast between certain colors, but they don’t restore normal color vision.
Gene therapy trials for achromatopsia have been underway since 2016. In 2022, researchers reported that two children who received treatment showed improved cone function and cone-supported vision. These trials are ongoing, and positive results could eventually open the door to testing gene therapies for other, more common forms of color vision deficiency.